Lexaria Bioscience Corp. (LEXX)

Market Cap	8.09M
Revenue (ttm)	340,791
Net Income (ttm)	-6.89M
Shares Out	8.09M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,196
Open	0.850
Previous Close	0.970
Day's Range	0.850 - 1.000
52-Week Range	0.649 - 3.595
Beta	1.14
Analysts	Strong Buy
Price Target	2.00 (+100.02%)
Earnings Date	Jul 14, 2023

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, ant...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: LEXX

Financial Performance

In 2022, LEXX's revenue was $255,397, a decrease of -64.66% compared to the previous year's $722,738. Losses were -$7.27 million, 80.5% more than in 2021.

Analyst Forecast

According to one analyst, the rating for LEXX stock is "Strong Buy" and the 12-month stock price forecast is $2.0.

Price Target

$2.0

(100.02% upside)

Analyst Consensus: Strong Buy